FeesSafety
Pluang+

Commercial National Financial posts Q3 2026 net income of $1.72M, slight dip from 2025 amid rising assets and share buybacks.

Company Fundamentals
27 Oct 2026, 00:10 WIB
GlobeNewsWire
View Source
Neutral
Commercial National Financial posts Q3 2026 net income of $1.72M, slight dip from 2025 amid rising assets and share buybacks.

Commercial National Financial Corporation reported a net income of $1.72 million for Q3 2026, slightly lower than $1.79 million in Q3 2025. The company saw a 2.4% increase in net interest income driven by higher securities income and lower funding costs, despite a 2.7% decline in total loans due to high interest rates and early payoffs. Total assets grew to $565 million, supported by increased wholesale funding and Federal Home Loan Bank borrowings. The company continues its share repurchase program with 91,333 shares bought back and $1.2 million allocated for future repurchases, maintaining strong capital and loan quality.

Commercial National Financial Corporation's Q3 2026 results provide context for readers. For those following the Financials sector, here is Pluang's market snapshot as of Oct 27, 2026 03:21 WIB: out of 142 priced US Financials stocks, 76 rose and 66 fell. Notable movers include BMNR at USD 20.91 with a 1-day change of -6.65%, AVAT at USD 1.16 with a 1-day change of -6.07% and Pluang order activity 75% Sell / 25% Buy, and WULF at USD 11.93 with a 1-day change of +5.39% and Pluang order activity 81% Sell / 19% Buy. The most notable figure is BMNR's -6.65% 1-day change.

More News

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...

Company Fundamentals
Neutral
1 hour ago
Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...

Market News
Bullish
1 hour ago
S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions has been accepted into the SAP PartnerEdge program, marking a key milestone in its growth. This partnership enhances S4A's ability to help organizations maximize their SAP investments, especially in areas like asset management and su...

Market News
Bullish
1 hour ago
SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

Public companies are facing new challenges for the 2027 proxy season due to changes in SEC policies, evolving shareholder activism strategies, and shifts in institutional investor voting. A virtual roundtable on October 28 will gather experts to disc...

Market News
Neutral
3 hours ago
Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo Inc., a leading provider of in-flight broadband connectivity, announced it will report its third quarter 2026 financial results on November 6, 2026, before the market opens. The company will hold a conference call with financial analysts the sam...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App